In this study, we have demonstrated that upregulation of PPARγ expression specifically in MES GSCs may serve as a molecular signature representing pathologic diagnosis biomarkers as well as therapeutic targets for that particular tumor subtype. The gene discussed is PPARG; the disease is neoplasm.